5 Results for "

Natural products analogue

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Natural products analogue" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-146958
CAS No.: 1638956-60-1
Purity:  98.03%
Target:  

Monoamine Oxidase

Research Areas:  

Neurological Disease

MAO-B-IN-8 is a potent reversible MAO-B inhibitor and an inhibitor of microglial production of neuroinflammatory mediator. MAO-B-IN-8 can be used for neurodegenerative disease research .
loading...
    loading...
Cat. No.: HY-N8609
CAS No.: 1262326-46-4
Uralsaponin C is an analogue of oleanane-type triterpenoid saponin. Uralsaponin C can be isolated from the roots of Glycyrrhiza uralensis Fisch .
loading...
    loading...
Cat. No.: HY-108553
CAS No.: 126463-64-7
Target:  

Proteasome Apoptosis

Research Areas:  

Cancer

Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis .
loading...
    loading...
Cat. No.: HY-W100681R
CAS No.: 1450-72-2
Research Areas:  

Others

Tetrahydropiperine (Standard) is the analytical standard of Tetrahydropiperine. This product is intended for research and analytical applications. Tetrahydropiperine, a cyclohexyl analogue of piperine, is the first natural aryl pentanamide from Piper longum . Tetrahydropiperine (compound 14) inhibits the cytochrome P450 (CYP) isoform CYP1A1/arylhydrocarbon hydroxylase (AHH; IC50=23 µM) .
loading...
    loading...
Cat. No.: HY-L0120V
170,269 compounds

“BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates.

Saturated, fused ring, spiro, and bridged systems with a tendency towards multiple chiral centers are highly privileged among natural products and marketed drugs yet these structures are very poorly represented in commercial libraries. This library addressed this market need by incorporating these privileged elements into the design of novel synthetic molecules with high molecular framework diversity, multiple stereogenic centers (≥2), and degree of saturation (Fsp3 > 0.5).